Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CAR-T cells are serial killers.

Alexander J Davenport1, Misty R Jenkins2, David S Ritchie1

  • 1Cancer Immunology Research; Peter MacCallum Cancer Center , East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne , Parkville, VIC Australia ; The ACRF Translational Research Laboratory; Royal Melbourne Hospital , Parkville, VIC Australia.

Oncoimmunology
|November 21, 2015
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026
Same author

Identification of T:B Cell Multimers After Bispecific T Cell Engagement, Using Both Conventional and Imaging Flow Cytometry.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2026
Same author

Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in Australia.

International journal of cancer·2026
Same author

Diet and risk of multiple myeloma: findings from a case-control study.

The British journal of nutrition·2026
Same author

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Expert opinion on pharmacotherapy·2026
This summary is machine-generated.

Chimeric antigen receptor (CAR) T cells can kill single and multiple tumor targets sequentially. However, CAR T cell killing efficacy decreases after 20 hours due to CAR down-regulation, limiting long-term anti-cancer immunity.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cell Therapy

Background:

  • Chimeric antigen receptor (CAR) T cells demonstrate significant success in treating hematological cancers.
  • Key aspects of CAR T cell biology, including their killing mechanisms and limitations, require further investigation.

Purpose of the Study:

  • To compare the killing capabilities of CAR T cells and T cell receptor (TCR) T cells within the same effector cell.
  • To investigate the dynamics of single and serial tumor target killing by CAR T cells.
  • To identify factors limiting the long-term efficacy of CAR T cell-mediated killing.

Main Methods:

  • Utilized a co-culture system to compare CAR T cell and TCR T cell killing functions.
  • Monitored tumor target elimination over time to assess single and serial killing events.
Keywords:
CART cell therapyserial killing

Related Experiment Videos

  • Quantified CAR expression levels to correlate with killing activity and duration.

    • Main Results:

    • CAR T cells demonstrated efficient killing of both single and multiple tumor targets in a sequential manner.
    • The ability of CAR T cells to kill targets was sustained for up to 20 hours.
    • CAR expression levels decreased significantly after 20 hours, correlating with reduced killing capacity.

    Conclusions:

    • CAR T cells possess potent capabilities for both single and serial tumor cell killing.
    • CAR down-regulation after approximately 20 hours represents a critical limitation to sustained CAR T cell anti-tumor activity.
    • Further research is needed to overcome CAR down-regulation and enhance the durability of CAR T cell therapy.